Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Of course news is eminent...they have to announce the price of the offering and the warrants.
Which is usually a day or two After the initial Announcement of the offering.
However, if you are spot on regarding what you are speculating for this company, I will be following you on all your in investment advice.
IMHO
Best of luck!
Still on the clinical trials.gov website.
https://clinicaltrials.gov/ct2/results?cond=&term=Delcath&cntry=&state=&city=&dist=&Search=Search
Not confusion Sam, only posting the facts from the clinical trials.gov website regarding current Delcath trials. Many people do not know that that type of information is out there, that it is public information, or how to access it. If I can help other investors, I am all for it. I know how confusing it was when I first started trading, and I appreciated the help I got from other investors. Point is, if I like your efforts and your DD (due diligence), I will click your profile and follow you. This helps everyone out with their credibility. I would hope other investors can do that for me as well.
As for confusion? I think not, only showing the data that I have found regarding this company, where I found it, and gave the links on where to find it. I NEVER BASH ANY STOCK, no matter how badly I dislike it, and I always write IMHO(In My Honest Opinion)
IMHO
Best of luck in all your trading!
That's the way I see it as well, and the more outstanding shares out there, the more they can hold in that last tranche of shares issued to them. For all we know, they may all be issued at this point. Especially if it is more than one entity as part of the note holders. What is 9.9% of total outstanding?
IMHO
Maybe they sold enough to get their original loan amount back? Could be holding now for an increase in PPS? The shares have already been promised in the deal at a discounted rare...win/win situation for the noteholders. There really is no benefit to sell at .04 over say .10? Sure, there probably are more shares to sell, but one major catalyst, and the whales will be here to buy up the float and get this thing moving...any rumor of a buy out...besides poincianamike, meaning...PR, or legitimate news channel, and it's off to the races. I'm not going to blow smoke and make PPS predictions, but I do expect big things in Q1.
IMHO
I agree that soothing needs to happen to get the PPS headed north, but I don't rule out the possibility of a partnership or out right buy out. Currently Delcath has three ongoing studies registered with NIH on the clinical trials website. Positive results on any one or all three of these studies can be a game changer for Delcath. Add in the fact that the FDA is working with Delcath to relax the protocol for enrollment and possible study completion dates...and that safety data had already been looked at by the "Independent Data Monitoring Committee". I would think, and this is just me thinking here...something big will be announced as soon as the balance sheets are cleaned up and the company patents are released! There have been several smaller biotechs bought out over the past year, and I see the chances of Delcath to be no different.
IMHO
Best of luck!
1. Melphalan Percutaneous Hepatic Perfusion for the Treatment of Unresectable Hepatic Malignancy https://clinicaltrials.gov/ct2/show/NCT03266042?term=Delcath&rank=2
I don't have the exact answer for that one, but I do know that DCTH has done this exact type of collateral backed loans with the patents in the past. Their note with Silicon Valley Bank had the same verbiage and had the patents tied up from 4/20/2012 until 6/8/2016.
The Trademark collateral with Hudson Bay was completed on 6/13/2016. Hopefully it won't be held for much longer, and we can start seeing some movement upwards!
IMHO
H2O, this shows where the 123M shares come into play.....when DCTH escaped from their debt and was able to regain control of their patents being held hostage by the senior noteholders, they did so by issuing 123,708,735 shares and $829,830.54 in cash. Many here believe that the company is getting ready for something big that required a major clean up of the balance sheets and rights to all the company assets.
IMHO
Best of luck!
Delcath Announces Exit from Convertible Note
NEW YORK, Dec. 29, 2017 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces on December 28, 2017, it entered into exchange agreements (collectively, “Exchange Agreements”), each by and between the Company and an investor from its June 2016 private placement of senior secured convertible notes (as further exchanged, the “Notes”) originally issued pursuant to that certain Securities Purchase Agreement, dated June 6, 2016, by and among the Company and such investors. Pursuant to the Exchange Agreements, we (i) extinguished our remaining $3,027,408 in outstanding obligations under the Notes in full, (ii) obtained a release of restrictions on $2,046,897.66 in restricted cash held in our control accounts, (iii) issued to the investors shares (the “Shares”) of our common stock (or rights (“Rights”) to receive common stock to the extent such issuance of Shares would otherwise result in the beneficial ownership by any such investor of more than 4.9% or 9.9% of our issued and outstanding stock), as applicable, of an aggregate of 123,708,735 shares of our common stock (in each case, subject to trading restrictions set forth in leak out agreements the Company separately entered into with each investor (collectively, the “Leak-Out Agreements”)) and (iv) a cash payment to the investors of $829,830.54 from the restricted cash held in our control accounts. The number of shares of the Company’s issued and outstanding common stock immediately following issuance of the initial Shares to the investors is 114,054,852.
The Rights may be exercised in whole or in part by an investor, without payment of additional consideration, at any time an investor would not beneficially own more than 4.9% or 9.9% (as set forth in the applicable Exchange Agreement) of the Company’s common stock (along with any shares of the Company’s common stock owned by any Attribution Parties) outstanding immediately after giving effect to such exercise. The Shares and Rights were issued in transactions exempt from registration under Section 4(a)(2) of the Securities Act of 1933, as amended, and the Shares and Rights were also issued in compliance with Section 3(a)(9) thereunder such that for Rule 144 purposes the holding period for the Shares and Rights and shares of Company common stock underlying the Rights may be tacked onto the holding period of the Notes.
The foregoing summaries of the terms of the Exchange Agreements and the Leak-Out Agreements do not purport to be complete and are qualified in their entirety by the terms of the Exchange Agreements and the Leak-Out Agreements attached to its Current Report on Form 8-K filed on December 29, 2017, as Exhibits 10.1 and 10.2, respectively, to the Current Report. Roth Capital Partners acted as financial advisor with respect to the transactions described herein.
Looking Great over the past two days!
Steadily climbing in the right direction. Hopefully the MM's will continue to back off and let this breathe a little bit. May be a sign that the 123,000,000 selling has slowed down and now they may consider holding? I am loving the fact that they have reached out to the FDA to get relaxed enrollment criteria. The fact that they are eliminating the note holders leverage over their patents, revamping the trial protocols, and have received interim safety data based on the IDMC 's decision to let the trial continue without modification...this is screaming to me a BO or big Partner stepping in could be right around the corner. Why else make such drastic changes with the note holders that had been in place for many months? Things are looking up here in a big way, and I for one am excited for the next couple months here!
IMHO
Best of luck everyone!
Ha ha...love it!
Great Article!
Thanks for posting wwwxxx62
Absolutely!
Can't have your hand in too many cookie jars! I seem to gravitate towards the bio stocks. I have a limited medical background, and mostly technical, so this one makes sence to me. I took up a small position of a little over 200k. This play seems very promising with their approved program in the EU. The FDA approval should be a no brained! Either way, I see a few spikes in the future!
Good to see you here Doc!
IMHO
Cytori Therapeutics jumps as Maxim sees it as takeover candidate
Jason AycockJan. 5, 2018 6:42 PM ET
Nanocap Cytori Therapeutics (NASDAQ:CYTX) vaulted in the last 15 minutes of the week's trading to a 74% gain after it was floated as a likely acquisition candidate by Maxim.
Analyst Jason Kolbert sees Takeda's (OTCPK:TKPYY) play for Tigenix (NASDAQ:TIG) as a positive sign for Cytori, since it makes a similar adipose-based product for regenerative medicine.
He has a price target of $5 vs. today's close of $0.47.
Volume was about 7.7M shares today vs. an average of less than 1M. Shares have drawn back slightly postmarket, -13%.
Source: Bloomberg
Basically Maxim reporter stated that CYTX would be a good Buyout Candidate seeing as Tigenix was made a significant offer from a Japanese company today. He said Cytori has just as much of a chance based on their research....and assigned a new price target.
I doubt a buyout will happen in the near future, but admit anything can happen!
Best of luck!
I am just as curious as to why now do the deal, but again, I am very glad they did. I have opened a pretty large position here, and am excited for the future.
I also just looked at the Clinical Trials.GOV website and see that they have another trial listed that is not yet recruiting?
"Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma" Maybe this will happen soon as well. It is a Phase3/4 trial.
Big things will be happening soon I am sure...just not sure what big thing that will be. Their other Phase 3 FOCUS trial is "Still Recruiting"..."Percutaneous Hepatic Perfusion vs. Best Alternative Care in Patients With Hepatic-dominant Ocular Melanoma (FOCUS)". Sure would be nice to know how many of the required 240 patients they have enrolled...or if they can go back to the FDA and ask for that N~Number to be reduced.
Time will tell, but 2018 looks to be very promising!
IMHO
Still holding here as well, but sold about 50K when it spiked, which it did. I have sell orders from .50 to 2.50. Was from .40 to 2.50...lol
Just surprised me that it filled is all.
I am not happy with the past performance of the company, and purchased more when the .33 offering was made available. was very depressed over the past month when it was trading at sub .25, so figured I would try to recoup a little if it bounced up.
Best of Luck Doc...but I honestly don't see a buyout soon. Not with the $10M they just collected from us shareholders. I was more expecting more trial announcements, and some interim data.
IMHO
Had the BO been publicized, the Note Holders would have asked for much more than the low priced warrants if a Cash Offer were to be presented. Having controlling interest over the Company's Patents is Huge! I am uncertain how/why the BOD ever let this happen, but it was a terrible mistake. I am surprised that they were to relinquish control with only 123M shares and warrants. The fact that they have shares now and warrants to purchase more shares keeps them fairly in the game when it comes to a possible BO too; because all warrants will have to be honored at the same per share price for a buy out. Either way, they stand to make millions should this make it all the way to FDA approval, or even if an offer comes in with positive Phase 3 data.
Win/Win in my book, but I for one am very glad that they took the offer and are not in control of the company's destiny anymore.
Best of Luck Sam!
IMHO
2018 Transformative year for DECN!
I am fairly confident we will have an outcome for the J&J litigation by EOY...not confident on the date, but I believe it is later in the year.
I am also fairly confident we will have a couple new patents from the USPTO, and fairly confident we will have strips being sold in big retail stores.
Sure those bashers are going to be negative until it actually happens, but I for one have confidence in Mr. Berman, and believe him when he states that new products are coming to market.
As for J&J...they feel threatened. They have had the market cornered for year selling at much higher prices, so why wouldn't they want to harass a smaller company selling the same product at less than half the price. Taking money out of a Giant's pocket is never easy; hence the delay in FDA approvals. Read into it what you want, but Major Players like J&J have people in various places who look out for their best interests...I'm not saying crooked, but may be tempted to look in the other direction, or move a paper to the bottom of the stack, or make a yes turn into a no.
Best of luck
IMHO
I almost pulled the trigger today on this one, but didn't get filled. I will have to wait till Monday to see if I can grab a few.
I have seen and ADCOM go well for a few companies, and I have seen it go horrible for one in particular. If you look at my history of posts, you can see the one that it went bad for. I had a gut feeling it was going to be bad, so I pulled out of that one around $2.80, and it dropped all the way to about .80 so not a good story. I was one of the lucky ones! I have however bought back into that one on hopes that they can get their CRL straightened out and go back to the FDA with a better pathway for approval.
The way I see LPCN right now is very positive, and I can't understand the downward pressure? With only labeling issues, this should be fairly easy approval and good outcome. But come January 10th, the writing will be out...not that the FDA has to accept the ADCOM's recommendation, but its about a 98% chance they do. I have only seen one where the FDA approved against the ADCOM recommendation not to approve.
Either way, best of luck!
I'll try again to get in next week
IMHO
Doc, hope you were able to flip a few there!
I had an unrealistic GTC Sell order in and got filled...
sold at .528 Someone wanted those shares very badly!!!
Wonder what the huge spike was? maybe a new institutional investor decided now was the time?
Guess we will hear something soon from the company?
IMHO
Ending the previous agreements with the note holders not only gave DCTH access to their cash that was on hold, it also removed the "liens" on their patents and any tangible asssets they had that could be sold in lieu for repayment of the notes. The fact that the company was able to remove those restrictions was tremendous to say the least. Now pending Phase 3 results that we can only speculate will be good...based on current European Sentiments, will allow the company to go to the bargaining table with all their cards to play. No restrictions from outside entities. 300-700 million shares or not, a buyout will take into consideration all outstanding shares and all warrants. Even if they partner, share count won't matter either because there will be a huge upfront payment, and institutional investors will swoop in just as soon as the market cap goes up and the up list to NASDAQ takes place again.Float will be devoured, no matter what the number!
Cancer treatments and cancer drugs are high on all Big Pharma lists, and I assure you BP will want a piece of this before they get to a FDA approval. I expect the offers to start coming in as soon as the data is released!
IMHO OF COURSE!
Could one of the Mods please Block this poster?
The constant bashing of other members is ridiculous!
Should be banned from IHUB!
Well Put JHstamwine!
Speaking like a Varsity player and not a Rookie!
My sentiments exactly...Great DD!
Do you not think a possible treatment for Liver Cancers is worth at a minimum $500M?
Well now, that would be $1.00 per share....a long way up from where we are at today wouldn't you say?
best of Luck! Some can't be saved~:)
Results from their other Phase 3 trial are due Q1, 2018.
There are a lot of people who are stuck in the .80's range, so this will stabilize soon and hopefully start growing legs in anticipation of the results.
I am only guessing here, but it looks like they will petition the FDA to allow the treatment to go forward based on the subgroups and the past Phase 2 studies. Wish they would have been more clear on the announcement! I have seen other drugs make the leap on failed Phase 3 studies...meaning those that didn't meet primary endpoints, but captured other promising data. Would just need to do a revision change for the primary treatments.
IMHO
Best of Luck!
I'm so glad there are so many saviors on this board!
Really...who needs to do their own DD?
Just follow those who bash the most and you'll do just fine! Lol, IMHO
Is Decision Diagnostics About To Announce A Buyout?
By Chris Sandburg October 19, 2017
Posted on
Decision Diagnostics Corp (OTCMKTS:DECN) is a company that we have looked at on a couple of occasions in the past under various circumstances here at Insider Financial and it’s one that, across the period, we have suggested could be set for longer-term upside revaluation if the various situations in question (read our previous coverage here to find out what we are talking about) mature to a reasonably smooth conclusion.
Over the last 30 days, we have seen a flurry of operational updates from the company, each of which has served to offer up different degrees of insight into where things stand operationally and, in line with these operational insights, we have seen the company appreciate considerably.
Right now, Decision Diagnostics goes for just shy of $0.15 a share. That’s 86% over the last six months. Over the last 30 days alone, it’s representative of a 156% appreciation.
Against the backdrop of this value advance, here is a look at what’s new from the company and what we are looking for next as supportive of a continuation of this upside momentum.
For those new to Decision Diagnostics, the company is a biotechnology stock that’s working to forge a path in the diabetes space.
Specifically, the company has designed a range of test strips that can be used with existing blood glucose monitoring technology (i.e. the handheld devices that diabetes sufferers use to measure that blood glucose on a daily basis) but that cost far less than do the currently available strips.
The idea is that, by reducing the cost, the company can pick up a large portion of this circa $6 billion market and at the same time can improve access to this sort of testing strip technology in developing nations, where monitoring equipment isn’t readily available due to cost prohibition.
At a glance, it’s development portfolio can look a bit confusing. However, to simplify, it comprises four products, called GenUltimate, GenSure, GenChoice and GenPrecis respectively.
Each has its own features and benefits but the overarching aim is to reduce costs while improving accuracy in both diabetes and prediabetes glucose level detection as well as making it a more accessible system for children.
Each of these technologies is in the late stage (with one already commercialized in various regions) and all should move from clinic to shelves at some point over the next 12 months. From an operational perspective, therefore, each represents its own potentially major catalyst for the company.
However, that’s not really what we are interested in right now.
Instead, we are looking at an announcement made on September 7 that detailed the fact that Decision Diagnostics has received a revised offer from a so-called proposed merger and acquisition partner.
To outline the situation, the company received a buyout offer (all cash) but declined it initially. The entity that made the offer (as yet unnamed) has now come back and increased it by 21%, which, as per management’s communication surrounding the matter, represents a substantial premium to the share price on announcement date (as mentioned, September 7), which came in at around seven cents a share.
The company stated that it’s not going to reveal any more information about the offer, or even debate it, before the launch of one of the above-mentioned product – the GenSure – is underway.
Been over a year since I asked to go back over $5
Happened then, maybe it will happen again!.
LOL
Sold out at $6.40, and added at the recent $4.50 level, hoping to make a few more Benjamin's here!
Best of luck everyone!
Great Post TP,
The fact that the IDMC...whom are requested by the FDA to look at the safety data for the treated patients in the trial already did their look and "Recommended to continue without modification" says to me that Positive Phase 3 results are around the corner.
Fact is, that it is the job of the Independent Safety Monitoring Board/Committee to recommend termination of the trials if they see any issues that could cause harm to the patients. Those beyond normal expected and/or accepted side effects.
No significant events says to me that the Efficacy and Pharmacokinetics of the trial vs. standard of care will be a slam dunk seeing as hundreds of procedures have already been conducted in Europe! More than 100 at a single hospital. Approved care in EU will soon be an approved care by the FDA!
IMHO
LONG DCTH
Follow the good Dr, and you could get those 2's...follow the PPS and you will get .047 and by tomorrow .05's.
IMHO
Update...I own about 250K shares, I am not shorting, and I would love for this to go to .02, because I will be buying a ton more!
I'm looking for the next run to .09, but If it dips to .02, I will double or triple my position...no problems here!
The noteholders will run out of shares, it is not the same death-spiral financing that the shorts here would have you believe. They were promised 112,000,000 shares, and that is it. What price they chose to execute at is entirely up to the holders of those notes. Should they chose to sell at .05 or .02? who knows? I however know that I would chose the higher PPS to sell, but a profit is a profit, so let them sell, and I will buy!
Best of Luck here!
Sorry Folks, you missed out on the low 4's...better get them before the 5's start printing again!
I hope so! I'd buy another 250,000
If only you could "Like" a comment!
Well put, and thanks for talking to management for us!
So, ready for the next leg up!
Hoping to stabilize around .30 after the flippers quit flipping it. Looks like a good turning place until news hits or an update on any one of the ongoing trials they have...That $10M had to go somewhere?
IMHO
Interim safety analysis was just released from their phase 3 trial seeking FDA approval. Seeing how it is already approved in Europe, this should be a no brainer! Just waiting for the final results.
IMHO.
Best of luck!
Great point SimSim!
Now until phase 3 is out, we should start to move up. Then who knows how high upon FDA Approval?
Best of luck!
Participating in the following conferences:
J.P. Morgan Annual Healthcare Conference: January 8, 2018
Systemic Sclerosis World Congress: February 15, 2018
Bordeaux, France
Operating burn rate reduced to ~$1M/month?
http://s1.q4cdn.com/221711767/files/doc_presentations/2017/Corp_Oct2017.pdf
• $11.4M in product and contract revenue in FY16
• $9M of cash and $14.2M of debt as of 6/30
• Restructuring implemented on Sept 1st, operating burn expected to be reduced to ~$1M/month
Here's to hoping for big things in 2018!
I'm in the same boat...couldn't get the funds together to participate in the offering, and kind of glad I didn't! I was able to quadruple my position at .26, so now my avg is about .38
Best of Luck Doc!
Most likely anticipation of trial updates.
After the 10M offering that was over subscribed, people are having to average down a bit. Shares were sold at .33, so as you can see we are a little under that PPS now.
The offering was supposed to garnish cash to futher trials and to keep the company running through 2018. CYTX has lots of Irons in the fire right now and have several catalysts that could sent this north of $1 at any point.
Right now there is still room to get in before we get back to the .33PPS were it should stabilize.
really oversold at this point and should continue to move back to that level soon.
IMHO
Best of luck
the fact that HAART utilizes two or three drugs is irrelevant when it comes to putting PRO-140 on the map for the world to see. That alone will bring in big Pharma to investigate what is going on at CYDY.
The fact that we are still on the OTC is the only reason I see that Institutional Investors have not jumped in. Some regulations stop big brokerages from taking positions in OTC stocks, so they are restricted to the big boards only. As soon as Combo results are out, which most of us think will be positive, we will be contacted for partnership or outright Buy Out.
Pears, I agree the real money will be the Single Therapy application should it ever get approved, but BP is not going to wait for that to happen before they act. Once it is proven to be safe and effective for Combo, lots of fireworks will be happening. I see our 93M Valuation as a total joke and expect to be partnered with upfront payments in the neighborhood of 100-250M with milestone payments until PDUFA and commercialization.
If not partnered before PDUFA, I would guess a BO for 250-500M or more.
Just my two cents...
IMHO
Good Luck to All in 2018